The clinical effects of Parkinson’s Disease (PD) are visually obvious, but the underlying pathology of PD is still not fully understood. In this slide deck, the course, natural history and prognosis of PD are discussed, including infographics on prodromal PD as well as the stages of PD. Observational cohorts of PD progression are also used to identify related biomarkers.

This slide deck has been developed in collaboration with the former Lundbeck International Neuroscience Foundation.

Index for
slide deck

Title

Course, Natural History and Prognosis
Course, Natural History and Prognosis

This presentation covers course, natural history and prognosis of Parkinson’s disease. The clinical effects of Parkinson’s disease (PD) are visually obvious, but the underlying pathology of PD is still not fully understood.

file_download Download slide in HQ

The course of Parkinson’s disease

The course of Parkinson’s disease
The course of Parkinson’s disease
file_download Download slide in HQ
The journey of Parkinson’s disease
The journey of Parkinson’s disease

The clinical effects of Parkinson’s disease (PD) are visually obvious, but the underlying pathology of PD is still not fully understood.[McCann et al., 2016] PD pathology is thought to spread from brain region to brain region over multiple long-distance relays, during lon…

file_download Download slide in HQ
Clinical symptoms and time course of Parkinson’s disease progression
Clinical symptoms and time course of Parkinson’s disease progression

The progression of PD is generally slow, taking place over years (often many years).[Kalia & Lang, 2015] While diagnosis tends to occur with the onset of motor symptoms, this can be preceded by a long prodromal phase of 15 years or more.[Goldman & Postuma, 2014] This prod…

file_download Download slide in HQ
Thresholds for the appearance of Parkinson’s disease symptoms
Thresholds for the appearance of Parkinson’s disease symptoms

Regions of the brain that are particularly vulnerable to Lewy pathology and degeneration during the earliest phase of PD include the olfactory bulb, a critical component of the sense of smell; the locus coeruleus, which produces noradrenaline and regulates sleep/wake cycl…

file_download Download slide in HQ
The therapeutic benefits of modifying the disease course
The therapeutic benefits of modifying the disease course

While there have been major advances in the management and reduction of PD-related symptoms, there is still no effective way of preventing or slowing the underlying neurodegeneration.[Athauda & Foltynie, 2015; Ferreira et al., 2013] As the disease becomes more extensive d…

file_download Download slide in HQ
Change in levodopa response over time – ‘wearing-off’
Change in levodopa response over time – ‘wearing-off’

Levodopa is the major symptomatic therapy for PD and provides benefit to virtually all patients.[Obeso et al., 2000] During the so-called ‘honeymoon’ period, the effects of levodopa tend to be long-lasting and side effects are tolerable.[Obeso et al., 2000] Beyond this ‘h…

file_download Download slide in HQ
Definitions of terms used in Parkinson’s disease
Definitions of terms used in Parkinson’s disease

The slide includes some basic definitions of terms used to describe the course of PD.

References:
Hametner E, Seppi K, Poewe W. The clinical spectrum of levodopa-induced motor complications. J Neurol 2010; 257 (Suppl 2): S268–275.

Kalia LV, Lang AE. Parkinson’s disease. L…

file_download Download slide in HQ
Drug-induced dyskinesias in Parkinson’s disease
Drug-induced dyskinesias in Parkinson’s disease

Levodopa-induced dyskinesias cover a broad clinical spectrum of different types of involuntary movements, ranging from chorea affecting the limbs, trunk, and head, slow dystonic movements, fixed dystonic postures, or (more rarely) myoclonus or ballism.[Hametner et al., 20…

file_download Download slide in HQ
Relationship between levodopa administration and motor fluctuations
Relationship between levodopa administration and motor fluctuations

As the extent of neurodegeneration in the substantia nigra becomes greater, its capacity to produce dopamine diminishes to the point where patients require larger doses of levodopa to maintain normal function.[Jenner, 2013]

Motor complications, such dyskinesia and motor f…

file_download Download slide in HQ

Prodromal Parkinson’s disease

Prodromal Parkinson’s disease
Prodromal Parkinson’s disease
file_download Download slide in HQ
MDS research criteria for prodromal Parkinson’s disease
MDS research criteria for prodromal Parkinson’s disease

The Movement Disorder Society (MDS) research criteria for identification of prodromal PD were designed solely for research purposes since, for now at least, the lack of effective treatments that are able to halt the progression of prodromal PD makes their clinical use unw…

file_download Download slide in HQ
Distribution of α-synuclein pathology in Parkinson’s disease
Distribution of α-synuclein pathology in Parkinson’s disease

The Lewy pathology and aggregated α-synuclein proteins associated with PD are not confined to the central nervous system (CNS); they can also be found in the peripheral nervous system at various sites around the body, such as the skin, gastrointestinal tract, and salivary…

file_download Download slide in HQ
The gastrointestinal system and Parkinson’s disease
The gastrointestinal system and Parkinson’s disease

!--?xml version="1.0" encoding="UTF-8" standalone="yes"?-- Neurons found in the enteric (gut) nervous system (ENS) require dopamine.[Rao & Gershon, 2016] Without dopamine, these neurons cannot properly control gastrointestinal motility.[Rao & Gershon, 2016] Animal studies…

file_download Download slide in HQ

Related content

image Image There are many aspects of Parkinson’s disease (PD) that can intensify the caregiver burden (e.g., impaired movement, sleep disorders, pain, cognitive impairment, etc.).
Perceived caregiver burden as Parkinson’s disease advances

There are many aspects of Parkinson’s disease (PD) that can intensify the caregiver burden

22.02.2025 Parkinson’s Disease
image Image An analysis published in 2020, and including indirect costs, estimated that the total annual economic cost of PD will exceed $79 billion by 2037 in the US alone.
The predicted burden of Parkinson’s disease in the USA up to 2037

An analysis published in 2020, and including indirect costs, estimated that the total annual economic cost of PD will exceed $79 billion by 2037 in the US alone

22.02.2025 Parkinson’s Disease
image Image The data shown on the illustration come from an analysis of US public and private administrative claims data, which estimated a prevalence of PD in the US of approximately 1 million people, equating to a total cost of $51.9 billion in 2017.{{3}} As shown on the illustration, slightly more than half of this cost was indirect, including non-medical costs, absenteeism, and disability payments.{{3}} Worldwide prevalence of PD is estimated to be around 10 million in 2024{{4,5}}, suggesting substantial indirect costs globally.
The indirect economic burden of Parkinson’s in the USA

In Parkinson’s disease, indirect costs make up a considerable proportion of the overall cost, and can be greater than the direct costs

22.02.2025 Parkinson’s Disease